Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Serum clinical safety markers, part II

From: Safety of TeaCrine®, a non-habituating, naturally-occurring purine alkaloid over eight weeks of continuous use

Variable T1 T2 T3 Time*group Time*group*gender
Urea Nitrogen (mg/dL)
 PLA 16 ± 4 15 ± 4 16 ± 5 Time p = 0.89 G*T*Ge p = 0.39
 LD 14 ± 3 14 ± 3 15 ± 3 G*T p = 0.34
 HD 15 ± 4 13 ± 4 14 ± 3
Creatinine (mg/dL)
 PLA 1.18 ± 0.2 0.96 ± 0.2 0.97 ± 0.2 Time p = 0.33 G*T*Ge p  = 0.046
 LD 0.97 ± 0.1 1.02 ± 0.2 1.03 ± 0.2 ‡ G*T p = 0.06
 HD 0.99 ± 0.2 1.01 ± 0.2 1.05 ± 0.2
Sodium (mmoL)
 PLA 140.65 ± 3 139.85 ± 2 140.95 ± 2 Time p  = 0.007 G*T*Ge p = 0.84
 LD 141.22 ± 2 140.17 ± 2 140.95 ± 3 G*T p = 0.67
 HD 141.19 ± 3 139.95 ± 2 † 140.24 ± 2
Potassium (mmoL)
 PLA 4.9 ± 0.4 4.7 ± 0.6 4.9 ± 0.5 Time p = 0.22 G*T*Ge p = 0.99
 LD 5.0 ± 0.6 4.8 ± 0.4 4.9 ± 0.5 G*T p = 0.97
 HD 4.9 ± 0.4 4.8 ± 0.4 4.9 ± 0.4
Chloride (mmoL)
 PLA 105.60 ± 2 104.45 ± 2 † 105.00 ± 2 Time p  = 0.006 G*T*Ge p = 0.60
 LD 105.89 ± 2 105.33 ± 2 104.84 ± 2 G*T p = 0.78
 HD 105.24 ± 2 104.33 ± 2 † 104.57 ± 2
Calcium (mg/dL)
 PLA 9.7 ± 0.5 9.5 ± 0.4 9.6 ± 0.4 Time p = 0.37 G*T*Ge p = 0.74
 LD 9.6 ± 0.3 9.6 ± 0.4 9.6 ± 0.3 G*T p = 0.20
 HD 9.8 ± 0.3 9.7 ± 0.4 9.7 ± 0.3
Carbon Dioxide (mmoL)
 PLA 24 ± 2 25 ± 2 24 ± 2 Time p = 0.65 G*T*Ge p = 0.95
 LD 26 ± 2 26 ± 2 25 ± 2 G*T p = 0.85
 HD 25 ± 2 25 ± 2 25 ± 2
  1. Abbreviations: PLA Placebo, LD Theacrine Low Dose, HD Theacrine High Dose, G Group, T Time, Ge Gender
  2. Symbols: ‡, increase from corresponding T1 value within the male TC-LD group (p < 0.05); †, different from corresponding T1 value (p < 0.05). Items in bold indicate a significant effect (p < 0.05) was observed
Back to article page